Oncology Precision Medicine Market Size & Share 2024 – 2032

Oncology Precision Medicine Market Size

The global oncology precision medicine market in 2023 was valued at USD 53.2 billion and is poised to grow at 10.4% CAGR over the forecast period. The rise in cancer cases worldwide is one of the key influencing factors influencing the growth in the market.

With the increasing number of cancer patients, there also emerges a greater need for combination therapies that are meant for particular gene mutations, thus improving the outcome of treatment. This emphasizes the increasing demand for precision oncology therapies that are needed in the modern healthcare environment for targeting and effective medicines that have fewer side effects.
 

In addition, the market is experiencing rapid growth caused by the increased awareness of oncology and the innovation in technologies like NGS (Next Generation Sequencing) and liquid biopsy. These techniques help detect particular mutations and markers that provide the basis for selecting suitable targeted therapy or immunotherapy for patients. The market is further bolstered by a growing demand for personalized cancer care and the integration of artificial intelligence (AI) in clinical decision-making.
 

Oncology precision medicine refers to a personalized approach of treating a specific type of cancer, depending on the particular genetic, molecular, or environmental characteristics of a patient’s tumor. Distinct from conventional cancer therapies which rely on a one-size fits all approach, oncology precision medicine focuses on identifying the presence of certain mutations or biomarkers in the tumor.
 

Oncology Precision Medicine Market Trends

• The International Agency for Research on Cancer (IARC) estimated that in 2022, 20 million new cancer cases were diagnosed, while 9.7 million people died due to cancer globally. Around 5 years post-diagnosis, 53.5 million people were reported alive.
   
• These figures are concerning highlighting the impact of cancer as 1 in 5 people are diagnosed with different forms of cancer at some point in their life. Unfortunately, 1 in 9 men and 1 in 12 women succumb due to complications from cancer, highlighting the need for more effective personalized treatment.
   
• This rise in the number of diagnosed cases of cancer is one of the primary reasons which is expanding the market for oncology precision medicine. There is an undeniable increase in the number of cancer cases diagnosed on a yearly basis which indicates a high demand for therapies that are tailored to specific genetic mutations.
   
• Precision medicine works by tailoring the individual genetic treatment of cancer which helps the patient recover faster with fewer side effects
  .
• The rise in cancer cases show the lack of effectiveness of general treatment and propel the use of more advanced therapies based on biomarkers in the clinic, hence further enhancing the market.
   

Oncology Precision Medicine Market Analysis

Based on cancer type, the market is classified into breast cancer, lung cancer, blood/ hematologic cancer, gastrointestinal cancer, skin cancer, bladder cancer, cervical cancer, head & neck squamous cell cancer, and other cancer types. The breast cancer segment dominated the market with 22.3% of market share in 2023.
 

• Breast cancer happens to be one of the most prominent cancers affecting women globally, resulting in an ever greater need for a personalized treatment.
   
• For instance, International Cancer Research Fund estimates that breast cancer is the second most prevalent cancer worldwide with a total of 2,296,840 new cases reported in 2022.
   
• Over the years, precision medicine made a significant impact with many targeted therapies such as those that focus on certain mutations like HER2, BRCA1, and BRCA2 breast cancer which improve treatment outcomes. The shift to focusing more on molecular profiling of patients and tailor-made treatment approaches has made this segment a leader in the market.
   

Based on route of administration, the oncology precision medicine market is segmented into oral, intravenous, and other routes of administration. The oral segment in 2023 was valued at USD 26.8 billion in 2023 and grow at 10.2% CAGR over the analysis period.
 

• One of the primary drivers includes the rising inclination towards oral medications as compared to intravenous ones which are more invasive and complicated.
   
• Also, the emergence of targeted therapies in precision medicine has fuelled the oral segment growth. Numerous precision oncology therapies such as kinase inhibitors and PARP inhibitors are designed as oral drugs to more easily target the cancer cells which have specific mutations in the tumours.
   
• Furthermore, the recent endorsement of several oral cancer medications approved by authorities highlights their effectiveness as well as safety in the treatment of cancer reinforcing their usage in precision medicine. This trend drives the market growth, since patients increasingly prefer non-invasive and efficient oral solutions to assist them in combatting cancer.

Based on molecule type, the oncology precision medicine market is segmented into small molecules and biologics. The small molecule segment held significant market share in 2023 and is anticipated to reach USD 70.1 billion by the end of forecast period.
 

• Small molecules can effectively target specific molecular pathways essential for cancer progression which makes them highly valuable in personalized cancer treatment.
   
• Apart from their therapeutic effectiveness, small molecules are advantageous because they are administered orally by the patients which greatly increases compliance and patient convenience.
   
• Moreover, because of the considerable investment in cancer research as well as the strong pipeline of new therapies, the small molecule segment is likely to grow further and consolidate its position within the market.
   

Based on drug class, the oncology precision medicine market is bifurcated into kinase inhibitors, immune checkpoint inhibitors, enzyme inhibitors, and other drug classes. The kinase inhibitors segment is expected to grow at 10.3% during the analysis timeframe.
 

• The high growth of this segment is due to the highly targeted action of these drugs and can selectively destroy major signalling pathways important for the multiplication and survival of cancer cells.
   
• Moreover, the higher incidence of certain cancers associated with specific genetic mutations like EGFR, BRAF, ALK, has resulted in more patients who can be treated with these targeted therapies.
   
• Additionally, the movement towards biomarker therapies and personalized medicine has allowed for the selection of patients with high likelihood of response to the kinase inhibitors, further enhancing this segment's position.

North America oncology precision medicine in 2023 accounted for USD 21.3 billion and is predicted to grow at 10.2% CAGR from 2024 - 2032.
 

• Growth in this region is driven by a high cancer incidence rate as well as well-established healthcare infrastructure that enables advanced research and development.
   
• The boost in innovation is attributable to regulatory assistance from the public and the private sectors in cancer research while the support from FDA accelerates the approval of precision therapies.
   
• Additionally, growing awareness and understanding about personalized medicine within both the doctors and patients fosters higher adoption rates, further promoting the growth of the market.
   

The U.S. oncology precision medicine market accounted for USD 19.7 billion in 2023 and is anticipated to reach USD 46 billion by 2032.
 

• In U.S., in 2023, the number of cancer patients and deaths related to it was anticipated to be about 1.95 million and 609,820 respectively, according to the American Cancer Society. As a result, this surging prevalence of cancer along with the rising patient population willing to opt personalized therapies allows the expansion of precision medicine in the U.S.
   
• In addition, the companies are trying to create new therapies for diseases and carrying out many clinical trials signifying the country’s leadership in biopharmaceutical innovation, contributing to the market growth.
   

China oncology precision medicine market is predicted to showcase remarkable growth over the forecast period.
 

• Rapid advancements in healthcare infrastructure and significant government initiatives to promote cancer research and treatment are facilitating the adoption of precision medicine.
   
• Additionally, the government of China is increasingly investing in genomic research and biotechnology, leading to the development of targeted therapies that are becoming more accessible to patients. These factors are expected to drive the growth of this market in the coming years.
   

India is expected to witness significant growth in global oncology precision medicine market.
 

• The expansion of advanced diagnostic centers and specialization for cancer treatments has made it possible for healthcare infrastructure to make precise medicine technology more prevalent in the country.
   
• Further, an increase in collaboration between Indian research institutions, and large global pharmaceutical companies enhances the innovation, while the emergence of local biotech firms focused on oncology contributes to the development of novel therapies.
   
• Collectively, these factors create a favourable environment for the expansion of the oncology precision medicine market in India.
   

Oncology Precision Medicine Market Share

In the oncology precision medicine market, there is stiff competition between the established pharmaceutical businesses and up-and-coming biotech companies. Some of the primary areas for competition are the ability to build effective targeting therapies, technology, collaboration with research clinics for biomarker, and business approvals. Considerable investments are being put into research and development aimed at broadening treatment portfolios and improving current treatments.
 

Oncology Precision Medicine Market Companies

Prominent players operating in the oncology precision medicine industry include:

• AbbVie
• Anticancer Bioscience
• AstraZeneca
• Bayer
• Blueprint Medicines Corporation
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Genentech
• GSK plc
• Merck & Co
• Novartis
• Pfizer
   

USPs for the top players:

• Established portfolios of FDA-approved targeted therapies and immunotherapies.
   
• Extensive oncology clinical trial networks across multiple regions.
   
• Advanced computational biology and AI-driven drug discovery capabilities.
   

Oncology Precision Medicine Industry News:  

• In March 2024, AstraZeneca announced its acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company specializing in next-generation radioconjugates (RCs). This acquisition advances AstraZeneca's goal of transforming cancer treatment by moving away from conventional therapies like chemotherapy and radiotherapy toward more targeted treatment options. The strategic acquisition enhances AstraZeneca's oncology portfolio.
   
• In March 2023, Pfizer Inc. and Seagen Inc. officially announced a merger agreement in which Pfizer will acquire Seagen, a leading biotechnology firm focused on discovering, developing, and commercializing innovative cancer treatments. This strategic acquisition aims to bolster Pfizer's oncology portfolio and strengthen its position in the fight against cancer, ultimately offering patients more advanced treatment options.
   

The oncology precision medicine market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Cancer Type

• Breast cancer
• Lung cancer
• Blood/ hematologic cancer
• Gastrointestinal cancer
• Skin cancer
• Bladder cancer
• Cervical cancer
• Head & neck squamous cell cancer
• Other cancer types

Market, By Route of Administration

• Oral
• Intravenous
• Other routes of administration

Market, By Molecule Type

• Small molecules
• Biologics

Market, By Drug Class

• Kinase inhibitors
• Immune checkpoint inhibitors
• Enzyme inhibitors
• Other drug classes

The above information is provided for the following regions and countries:

• North America
• U.S.
• Canada

• Europe
• Germany
• UK
• France
• Spain
• Italy
• Netherlands
• Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Latin America
• Brazil
• Mexico
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE